Literature DB >> 8034435

Comparison of the effects of three haemodialysis membranes on vancomycin disposition.

J Alwakeel1, T A Najjar, M J al-Yamani, S Huraib, A al-Haider, H Abu-aisha.   

Abstract

Polysulfone (PSF) and polyacrylonitrile (PAN) were recently introduced haemodialysis (HD) membranes. The effect of each on vancomycin disposition was compared with cuprophan (SCE) in 12 chronic HD patients who received 14 infusions. Vancomycin (1 g) was infused over 1 hour, followed by three 4-hour HD sessions over 5 days, beginning 1 hour after the end of infusion. The intradialytic clearances of vancomycin were 73, 54 and 15 ml/min for PSF, PAN and SCE, respectively. At the end of the third HD session, vancomycin concentration dropped to subtherapeutic level (< 7.5 micrograms/ml) only in patients dialysed with PSF and PAN. The corresponding elimination half-lives (t1/2 beta) were 61, 60 and 86 hours for the three membranes, respectively. According to these findings, vancomycin should be given every three HD sessions for PSF and PAN. The dosage interval should be extended up to every 5 HD sessions for patients on SCE. The peak (mean +/- S.D.) obtained one hour after the end of infusion was 34.2 +/- 11.4 micrograms/ml, which is within the therapeutic range.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8034435     DOI: 10.1007/bf02768291

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  11 in total

Review 1.  Dialysis membrane biocompatibility.

Authors:  C Basile; T Drüeke
Journal:  Nephron       Date:  1989       Impact factor: 2.847

2.  Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers.

Authors:  D M Lanese; P S Alfrey; B A Molitoris
Journal:  Kidney Int       Date:  1989-06       Impact factor: 10.612

3.  Hemodialysis clearance of theophylline.

Authors:  G Levy; T P Gibson; W Whitman; J Procknal
Journal:  JAMA       Date:  1977-04-04       Impact factor: 56.272

4.  Pharmacokinetics of vancomycin in patients with various degrees of renal function.

Authors:  G R Matzke; R W McGory; C E Halstenson; W F Keane
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

5.  Pharmacokinetics of vancomycin in anuria.

Authors:  B A Cunha; R Quintiliani; J M Deglin; M W Izard; C H Nightingale
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

6.  Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes.

Authors:  J Böhler; P Reetze-Bonorden; E Keller; A Kramer; P J Schollmeyer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

8.  Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis.

Authors:  S Eykyn; I Phillips; J Evans
Journal:  Br Med J       Date:  1970-07-11

9.  Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure.

Authors:  C C Tan; H S Lee; T Y Ti; E J Lee
Journal:  Ther Drug Monit       Date:  1990-01       Impact factor: 3.681

10.  Vancomycin therapy for serious staphylococcal infections in chronic hemodialysis patients.

Authors:  M H Bierman; C A Needham-Walker; M Hammeke; J D Egan
Journal:  J Dial       Date:  1980
View more
  1 in total

Review 1.  Clinical review: use of vancomycin in haemodialysis patients.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Lucile Mercadal; Gilbert Deray
Journal:  Crit Care       Date:  2002-06-10       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.